Free Trial

Klotho Neurosciences (KLTO) Competitors

Klotho Neurosciences logo
$0.78 -0.02 (-1.90%)
As of 08/14/2025 04:00 PM Eastern

KLTO vs. CYBN, TIL, LYEL, CRDF, LFVN, DERM, ACRS, RAPT, SLS, and PBYI

Should you be buying Klotho Neurosciences stock or one of its competitors? The main competitors of Klotho Neurosciences include Cybin (CYBN), Instil Bio (TIL), Lyell Immunopharma (LYEL), Cardiff Oncology (CRDF), Lifevantage (LFVN), Journey Medical (DERM), Aclaris Therapeutics (ACRS), Rapt Therapeutics (RAPT), SELLAS Life Sciences Group (SLS), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry.

Klotho Neurosciences vs. Its Competitors

Klotho Neurosciences (NASDAQ:KLTO) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

20.1% of Klotho Neurosciences shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 26.7% of Klotho Neurosciences shares are held by insiders. Comparatively, 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cybin's return on equity of -37.58% beat Klotho Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Klotho NeurosciencesN/A -1,779.01% -275.01%
Cybin N/A -37.58%-36.59%

Klotho Neurosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Klotho NeurosciencesN/AN/A-$6.15M-$0.36-2.16
CybinN/AN/A-$57.88M-$3.88-1.85

Cybin has a consensus price target of $85.00, indicating a potential upside of 1,085.50%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Klotho Neurosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Klotho Neurosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cybin
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

Klotho Neurosciences has a beta of 10.9, indicating that its share price is 990% more volatile than the S&P 500. Comparatively, Cybin has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

In the previous week, Klotho Neurosciences had 4 more articles in the media than Cybin. MarketBeat recorded 7 mentions for Klotho Neurosciences and 3 mentions for Cybin. Klotho Neurosciences' average media sentiment score of 0.27 beat Cybin's score of 0.24 indicating that Klotho Neurosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Klotho Neurosciences
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cybin
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Klotho Neurosciences and Cybin tied by winning 7 of the 14 factors compared between the two stocks.

Get Klotho Neurosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KLTO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KLTO vs. The Competition

MetricKlotho NeurosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$36.57M$2.48B$5.61B$9.84B
Dividend YieldN/A1.76%4.61%4.07%
P/E Ratio-2.1622.0530.2925.74
Price / SalesN/A742.42463.41115.83
Price / CashN/A184.4138.2159.48
Price / Book19.484.838.826.15
Net Income-$6.15M$31.61M$3.25B$265.06M
7 Day Performance-13.85%4.55%3.70%2.60%
1 Month Performance-42.30%5.69%5.84%2.83%
1 Year PerformanceN/A12.71%29.92%25.58%

Klotho Neurosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KLTO
Klotho Neurosciences
N/A$0.78
-1.9%
N/AN/A$36.57MN/A-2.16N/AUpcoming Earnings
CYBN
Cybin
2.6131 of 5 stars
$7.57
-1.4%
$85.00
+1,022.9%
N/A$178.58MN/A-1.7350News Coverage
TIL
Instil Bio
3.0994 of 5 stars
$26.99
+9.1%
$119.00
+340.9%
+170.1%$177.05MN/A-2.25410News Coverage
Earnings Report
LYEL
Lyell Immunopharma
3.3013 of 5 stars
$11.43
+0.5%
$15.00
+31.2%
-55.2%$176.71M$60K-0.46270Trending News
Earnings Report
Gap Down
CRDF
Cardiff Oncology
2.0472 of 5 stars
$2.57
+2.4%
$11.70
+355.3%
+11.9%$170.98M$680K-2.9520
LFVN
Lifevantage
4.2195 of 5 stars
$13.44
+1.1%
$30.50
+126.9%
+71.0%$169.21M$200.16M19.48260
DERM
Journey Medical
1.881 of 5 stars
$7.21
+1.0%
$9.50
+31.8%
+52.5%$167.99M$56.13M-18.4990News Coverage
Earnings Report
Analyst Forecast
Analyst Revision
ACRS
Aclaris Therapeutics
2.6379 of 5 stars
$1.55
-0.6%
$8.71
+462.2%
+44.4%$167.83M$18.72M-1.12100
RAPT
Rapt Therapeutics
4.5879 of 5 stars
$10.10
-6.1%
$20.57
+103.7%
-34.3%$167.05M$1.53M-0.5380Analyst Forecast
SLS
SELLAS Life Sciences Group
2.8757 of 5 stars
$1.62
+1.9%
$7.00
+332.1%
+29.2%$161.64M$1M-4.2610News Coverage
Earnings Report
PBYI
Puma Biotechnology
4.1339 of 5 stars
$3.22
+1.3%
$7.00
+117.4%
+95.9%$159.81M$230.50M4.18200Gap Down

Related Companies and Tools


This page (NASDAQ:KLTO) was last updated on 8/15/2025 by MarketBeat.com Staff
From Our Partners